UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO. CONFIRMATION NO		
10/618,194	07/11/2003	Eva M. Sevick-Muraca	017575.0700	4277	
5073 BAKER BOTT	7590 05/03/201 S L.L.P.	EXAMINER			
2001 ROSS AV	ENUE	WINAKUR, ERIC FRANK			
SUITE 600 DALLAS, TX 7	75201-2980	ART UNIT	PAPER NUMBER		
			3768		
			NOTIFICATION DATE	DELIVERY MODE	
			05/03/2010	ELECTRONIC	

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

ptomail1@bakerbotts.com glenda.orrantia@bakerbotts.com

		Annliaati	on No	Applicant(s)			
Office Action Summary		Applicati					
		10/618,19	94	SEVICK-MURACA ET AL			
		Examine	•	Art Unit			
		Eric F. Wi	nakur	3768			
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply							
A SHORT WHICHE - Extensions after SIX (i - If NO period - Failure to i Any reply i	TENED STATUTORY PERIOD FOVER IS LONGER, FROM THE MAS of time may be available under the provisions of 5) MONTHS from the mailing date of this community of for reply is specified above, the maximum statically within the set or extended period for reply we received by the Office later than three months after them adjustment. See 37 CFR 1.704(b).	ALING DATE OF THE 57 CFR 1.136(a). In no even ication. Utory period will apply and will, by statute, cause the approximation of the properties of the approximation of the province of the approximation.	HIS COMMUNICATION ent, however, may a reply be timil expire SIX (6) MONTHS from lication to become ABANDONEI	L. ely filed the mailing date of this communic () (35 U.S.C. § 133).			
Status							
2a)∏ Thi 3)∏ Sin	sponsive to communication(s) filed s action is FINAL . 2! ce this application is in condition for seed in accordance with the practice.	o)⊠ This action is r or allowance except	on-final. for formal matters, pro		s is		
Disposition of	of Claims						
4a) 5)⊠ Cla 6)⊠ Cla 7)□ Cla 8)□ Cla	im(s) <u>1-20</u> is/are pending in the ap Of the above claim(s) is/are im(s) <u>1-14</u> is/are allowed. im(s) <u>15-20</u> is/are rejected. im(s) is/are objected to. im(s) are subject to restricting	withdrawn from co					
Application	Papers						
10)☐ The App Rep	specification is objected to by the drawing(s) filed on is/are: elicant may not request that any object placement drawing sheet(s) including to oath or declaration is objected to	a) accepted or b) ion to the drawing(s) the correction is required.	ne held in abeyance. See ed if the drawing(s) is obj	37 CFR 1.85(a). ected to. See 37 CFR 1.12			
Priority unde	er 35 U.S.C. § 119						
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 							
2) Notice of 3 Notice of 3	References Cited (PTO-892) Draftsperson's Patent Drawing Review (PT n Disclosure Statement(s) (PTO/SB/08) s)/Mail Date 12/9/09.	O-948)	4) Interview Summary Paper No(s)/Mail Da 5) Notice of Informal Pa	te			

DETAILED ACTION

Double Patenting

1. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., *In re Berg*, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement.

Application/Control Number: 10/618,194 Page 3

Art Unit: 3768

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

2. Claims 15 - 23 are rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 15, 16, 26, 28, 32, and 33 of U.S. Patent No. 5,865,754 (cited by Applicant) in view of Hayashi (previously cited). The claims of the patent cover a method of tissue analysis that includes all of the features of the claims of the instant application except identifying the particular tissue that is examined, the particular fluorescent agent that is used, and the emission wavelengths of the fluorescent agent. Further, the claim of the instant application differs from the claim of the patent in that the patent claim does not particularly detail rejecting excitation light. Hayashi teaches a fluorescent imaging technique for imaging sentinel lymph nodes using indocyanine green, having a fluorescence spectrum as given in Figure 4 when excited by near-infrared light. Further, Hayashi teaches including a stimulating light cutoff filter prior to the detector. It would have been obvious to one of ordinary skill in the art at the time of the invention to implement the claimed method of the patent to perform measurements on sentinel lymph nodes, since the patented method is intended to perform measurements on tissue and Hayashi teaches a manner to obtain fluorescence measurements from a tissue of interest, namely a sentinel lymph node, using a fluorescent agent. In addition, Hayashi teaches to include a cutoff filter prior to the fluorescence light detector.

Response to Arguments

Art Unit: 3768

3. Applicant's arguments, see remarks, filed 1/4/10, with respect to the rejections under 112, first and second paragraph and 103(a) have been fully considered and are persuasive. The above rejections of the claims have been withdrawn.

Allowable Subject Matter

4. Claims 1 - 14 are allowed.

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Eric F. Winakur whose telephone number is 571/272-4736. The examiner can normally be reached on M-Th, 7:30-5; alternate Fri.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Long Le can be reached on 571/272-0823. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Application/Control Number: 10/618,194

Art Unit: 3768

Primary Examiner, Art Unit 3768

Page 5